The Use of Bisphosphonates May Help Lengthen Life of Artific

1. The Use of Bisphosphonates May Help Lengthen Life of Artificial Joints: Study 

2. Osteoporosis drugs may offer more benefits that extend from people with osteoporosis to patients with certain cancers, a 2011 study suggests, explaining how bisphosphonates may also provide assistance to individuals who may have gone through hip and knee replacement surgeries by extending the life of their artificial joints.� However, as promising as the findings may have been, medical experts highlight how some important questions remain unanswered especially those that look into the risks bone drugs may bring to osteoarthritic patients.� Popular bisphosphonate drugs such as Fosamax and related adverse events have reportedly drawn controversy over the past decade, which in some cases have resulted to compensatory claims from several former users.� In fact,�New Jersey Fosamax trials scheduled for 2012�duly set early this year may have already commenced.

3. Osteoarthritis is a common joint disorder characterized by the wear and tear of the joints brought about by the breakdown of cartilage, as defined by medical journals.� It stands similar at certain aspects to osteoporosis as a degenerative disease commonly acquired through ageing which has been prevalent among elderly men and women.� Over 700,000 hip and knee replacement procedures annually take place in the United States, government statistics reports, further reckoning how osteoarthritis has played a significant role in more than nine out of 10 joint replacement surgeries in patients. While previously conducted studies have reportedly looked into how bone drugs may increase an implant�s survival, United Kingdom based researchers who have had their study published in the British Medical Journal was the first to make a follow through in patients to track bisphosphonate effects� long-term outcomes in a five-year period.

4. The research team identified study cohorts of about 42,000 individuals over 40 years of age who had hip and knee joint replacements between 1986 through 2006 using a health registry of over three million people in the U.K.� After having determined an approximate of nearly five percent bisphosphonate users among the participants, study authors revealed that less than one percent of implanted patients have undergone repeat replacement procedures, compared to less than two percent of non-bisphosphonate users. Despite the benefits that osteoporosis drugs may offer to osteoarthritic recipients of artificial implants, medical experts note how bisphosphonates may also bring about unanticipated side effects as were other medications.� Certain bisphosphonates such as Fosamax have also been linked to potentially serious adverse events, some of which have reportedly led to legal repercussions.� Comprehensive and regularly updated information at�http://www.fosamax-lawsuit.net�may be of great help to those who may be seeking for legal assistance.

5. � Sources: ncbi.nlm.nih.gov/pubmedhealth/PMH0001460/ arthritis.webmd.com/news/20111206/study-bone-drugs-may-increase-longevity-joint-replacement-implants